Hillevax Inc (NASDAQ:HLVX) — Market Cap & Net Worth
Market Cap & Net Worth: Hillevax Inc (HLVX)
Hillevax Inc (NASDAQ:HLVX) has a market capitalization of $104.76 Million ($104.76 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #19126 globally and #4409 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hillevax Inc's stock price $2.09 by its total outstanding shares 50125541 (50.13 Million). Also see total assets of Hillevax Inc for a full breakdown of the balance sheet.
Hillevax Inc Market Cap History: 2022 to 2025
Hillevax Inc's market capitalization history from 2022 to 2025. Data shows change from $838.60 Million to $104.76 Million (-47.94% CAGR). Also see HLVX cash generation efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
Hillevax Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #545 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #1849 of 3165 |
Weight: Hillevax Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Hillevax Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hillevax Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check HLVX share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of HLVX by Market Capitalization
Companies near Hillevax Inc in the global market cap rankings as of September 18, 2026. Review Hillevax Inc tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Hillevax Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Hillevax Inc Historical Marketcap From 2022 to 2025
Between 2022 and today, Hillevax Inc's market cap moved from $838.60 Million to $ 104.76 Million, with a yearly change of -47.94%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $104.76 Million | +0.97% |
| 2024 | $103.76 Million | -87.10% |
| 2023 | $804.51 Million | -4.06% |
| 2022 | $838.60 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Hillevax Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $104.76 Million USD |
| MoneyControl | $104.76 Million USD |
| MarketWatch | $104.76 Million USD |
| marketcap.company | $104.76 Million USD |
| Reuters | $104.76 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hillevax Inc
HilleVax, Inc., a clinical-stage biopharmaceutical company, develops and commercializes vaccines in the United States. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. It has a license agreement with Takeda Vaccines, Inc. to develop and commercialize HIL-214 pharmaceutical prod… Read more